CERT

Certara Inc

Add to Watchlist

Advanced Chart

11.000

-0.02(-0.181%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.020

Open

11.020

VWAP

11.03

Vol

13.29K

Mkt Cap

1.77B

Low

11.000

Amount

146.67K

EV/EBITDA(TTM)

18.43

Total Shares

160.84M

1.90B

EV/OCF(TTM)

18.73

P/S(TTM)

4.37

Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development (MIDD) in the global biopharmaceutical industry. It accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. It delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. It offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

113.39M

+6.97%

0.139

-0.81%

107.00M

+6.61%

0.115

-23.46%

104.66M

+10.37%

0.110

-15.1%

Estimates Revision

The market is revising Downward the revenue expectations for Certara, Inc. (CERT) for FY2025, with the revenue forecasts being adjusted by -0.03% over the past three months. During the same period, the stock price has changed by -6.62%.

Revenue Estimates for FY2025

Revise Downward

-0.03%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-6.62%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast CERT.O stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERT.O is 14.75 USD with a low forecast of 13.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

4 Hold

0 Sell

Moderate Buy

Current: 11.000

Low

13.00

Averages

14.75

High

16.00

Current: 11.000

Low

13.00

Averages

14.75

High

16.00

Morgan Stanley

Equal Weight

initiated

$16

2025-07-03

Reason

Morgan Stanley

Price Target

$16

2025-07-03

initiated

Equal Weight

Reason

Morgan Stanley assumed coverage of Certara with an Equal Weight rating and $16 price target. The firm says it awaits further potential updates on Certara's strategic review of the regulatory services business and management commentary regarding the near- or mid-term impact that may result from Certara's opportunity set coming from the FDA's previous announcement to gradually reduce animal testing in favor of new approach methodologies.

Barclays

Luke Sergott

Equal Weight -> Overweight

upgrade

$11 -> $14

2025-05-08

Reason

Barclays

Luke Sergott

Price Target

$11 -> $14

2025-05-08

upgrade

Equal Weight -> Overweight

Reason

Barclays analyst Luke Sergott upgraded Certara to Overweight from Equal Weight with a price target of $14, up from $11. The firm believes the company is more favorably positioned with potential macro and policy headwinds versus the majority of its peers sector. Shares at current levels offer an attractive entry point, the analyst tells investors in a research note. While it is still early days, Certara's simulation modeling functions more in the earlier stages of drug discovery, and the business is well positioned to capture Tailwinds from the transition away from animal models, contends Barclays.

Keybanc

Scott Schoenhaus

Buy

Maintains

$15 → $18

2025-04-16

Reason

Keybanc

Scott Schoenhaus

Price Target

$15 → $18

2025-04-16

Maintains

Buy

Reason

KeyBanc raised the firm's price target on Certara to $18 from $15 and keeps an Overweight rating on the shares. . Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.

Baird

Joe Vruwink

Hold

Maintains

$9 → $13

2025-04-11

Reason

Baird

Joe Vruwink

Price Target

$9 → $13

2025-04-11

Maintains

Hold

Reason

Baird analyst Joe Vruwink raised the firm's price target on Certara to $13 from $9 and keeps a Neutral rating on the shares. The firm updated its model after the FDA offered a strong endorsement for Biosimulation.

Barclays

Luke Sergott

Hold

Maintains

$13 → $11

2025-04-10

Reason

Barclays

Luke Sergott

Price Target

$13 → $11

2025-04-10

Maintains

Hold

Reason

Barclays lowered the firm's price target on Certara to $11 from $13 and keeps an Equal Weight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.

Barclays

Luke Sergott

Hold

Maintains

$12 → $13

2025-02-28

Reason

Barclays

Luke Sergott

Price Target

$12 → $13

2025-02-28

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Certara Inc (CERT.O) is 22.19, compared to its 5-year average forward P/E of 51.53. For a more detailed relative valuation and DCF analysis to assess Certara Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

51.53

Current PE

22.19

Overvalued PE

87.62

Undervalued PE

15.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

26.38

Current EV/EBITDA

14.00

Overvalued EV/EBITDA

38.09

Undervalued EV/EBITDA

14.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

8.97

Current PS

4.04

Overvalued PS

13.35

Undervalued PS

4.60

Financials

Annual

Quarterly

FY2025Q2

YoY :

+12.06%

104.57M

Total Revenue

FY2025Q2

YoY :

-286.53%

5.19M

Operating Profit

FY2025Q2

YoY :

-84.35%

-1.97M

Net Income after Tax

FY2025Q2

YoY :

-87.50%

-0.01

EPS - Diluted

FY2025Q2

YoY :

+192.75%

10.82M

Free Cash Flow

FY2025Q2

YoY :

+10.02%

47.53

Gross Profit Margin - %

FY2025Q2

YoY :

+36.75%

19.09

FCF Margin - %

FY2025Q2

YoY :

-86.05%

-1.88

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

638.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

3.7K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

638.0K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CERT.O News & Events

Events Timeline

2025-08-06 (ET)

2025-08-06

17:09:58

Certara sees FY25 adjusted EPS 42c-46c, consensus 46c

2025-08-06

17:08:14

Certara reports Q2 adjusted EPS 7c, consensus 10c

2025-08-04 (ET)

2025-08-04

05:12:37

Certara announces EMA qualification of Simcyp Simulator

News

9.5

08-07Newsfilter

Certara, Inc. (CERT) Q2 2025 Earnings Call Transcript

9.5

08-07NASDAQ.COM

Certara (CERT) Q2 Revenue Jumps 12%

5.0

07-31Newsfilter

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

People Also Watch

FAQ

What is Certara Inc (CERT.O) stock price today?

The current price of CERT.O is 11 USD — it has decreased -0.18 % in the last trading day.

CERT

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CERT.O News & Events

Events Timeline

News

People Also Watch

FAQ

What is Certara Inc (CERT.O) stock price today?

What is Certara Inc (CERT.O)'s business?

What is the price predicton of CERT.O Stock?

What is Certara Inc (CERT.O)'s revenue for the last quarter?

What is Certara Inc (CERT.O)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Certara Inc (CERT.O)'s fundamentals?

How many employees does Certara Inc (CERT.O). have?

What is Certara Inc (CERT.O) market cap?